secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-05-11T20:05:17+00:00
Accession:  0001193125-26-216731
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028
--------------------------------------------------------------------------------

- Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.
- Positive combo data with enzalutamide: median rPFS 7.0 mo overall, 10.1 mo in 1 prior ARPI.
- Pivotal Phase 3 protocol for roxadustat in LR-MDS being finalized after FDA feedback; trial start H2 2026.
- Revenue $3.7M (up from $2.7M); net loss $15.1M vs $16.8M YoY.
- Cash and equivalents $100.3M; sufficient to fund operations into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/0001193125-26-216731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526216731/kynb-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer